ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 792,65
1,44%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Rocket Pharmaceuticals Inc (RCKT)

  7. Rocket Pharmaceuticals Inc (RCKT) Actualités

RCKT

Rocket Pharmaceuticals (RCKT)

Rocket Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RCKT
DateHeureSourceTitreSymboleSociété
02/04/202412h00Business WireRocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi AnemiaNASDAQ:RCKTRocket Pharmaceuticals Inc
26/03/202421h01Business WireRocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership TeamNASDAQ:RCKTRocket Pharmaceuticals Inc
05/03/202400h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
29/02/202421h54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
26/02/202422h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RCKTRocket Pharmaceuticals Inc
26/02/202422h01Business WireRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202423h28Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
13/02/202413h00Business WireRocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)NASDAQ:RCKTRocket Pharmaceuticals Inc
29/01/202421h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
02/01/202422h01Business WireRocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RCKTRocket Pharmaceuticals Inc
13/12/202302h42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
12/12/202313h00Business WireRocket Pharmaceuticals Appoints R. Keith Woods to Board of DirectorsNASDAQ:RCKTRocket Pharmaceuticals Inc
07/11/202322h40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RCKTRocket Pharmaceuticals Inc
06/11/202322h04Business WireRocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
21/10/202300h37Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
19/10/202313h00Business WireRocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)NASDAQ:RCKTRocket Pharmaceuticals Inc
02/10/202313h00Business WireRocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)NASDAQ:RCKTRocket Pharmaceuticals Inc
26/09/202322h01Business WireRocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines ConferenceNASDAQ:RCKTRocket Pharmaceuticals Inc
20/09/202322h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RCKTRocket Pharmaceuticals Inc
19/09/202322h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
13/09/202313h37IH Market NewsWednesday’s Wall Street Highlights: Apple, Xpeng, GoDaddy, BP, UBS, Nike, and moreNASDAQ:RCKTRocket Pharmaceuticals Inc
13/09/202306h01Business WireRocket Pharmaceuticals Announces Pricing of Public Offering of Common StockNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202323h28Dow Jones NewsRocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease TreatmentNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202322h55Dow Jones NewsRocket Pharmaceuticals Reaches FDA Alignment in Danon Heart Disease Treatment TrialNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202322h02Business WireRocket Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202322h01Business WireRocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon DiseaseNASDAQ:RCKTRocket Pharmaceuticals Inc
06/09/202322h05Business WireRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:RCKTRocket Pharmaceuticals Inc
10/08/202313h00Business WireRocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
27/06/202301h49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RCKTRocket Pharmaceuticals Inc
23/06/202322h28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RCKTRocket Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RCKT

Dernières Valeurs Consultées

NYSE
MRK
Merck
EU
BEL20
Bel 20
EU
CAP
Capgemini
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
NYSE
KO
Coca Cola
NYSE
MCD
McDonalds
EU
GLE
Societe Generale
EU
BN
Danone
EU
RNO
Renault
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
EU
ORA
Orange
EU
AF
Air FranceKLM
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés